Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H. Müller-Tidow C, et al. Among authors: dohner h. Br J Haematol. 2013 Oct;163(2):214-22. doi: 10.1111/bjh.12518. Epub 2013 Aug 16. Br J Haematol. 2013. PMID: 24033250 Free article. Clinical Trial.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. Fiedler W, et al. Among authors: dohner h. Blood. 2005 Feb 1;105(3):986-93. doi: 10.1182/blood-2004-05-1846. Epub 2004 Sep 30. Blood. 2005. PMID: 15459012 Free article. Clinical Trial.
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D. Ringhoffer M, et al. Among authors: dohner h. Br J Haematol. 2005 Aug;130(4):604-13. doi: 10.1111/j.1365-2141.2005.05663.x. Br J Haematol. 2005. PMID: 16098076 Free article. Clinical Trial.
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Ringhoffer M, Harsdorf Sv, Schmitt M, Wiesneth M, Zenz T, Stilgenbauer S, Greiner J, Döhner K, Marx M, Döhner H, Bunjes D. Ringhoffer M, et al. Among authors: dohner k, dohner h. Br J Haematol. 2007 Jan;136(1):127-30. doi: 10.1111/j.1365-2141.2006.06404.x. Br J Haematol. 2007. PMID: 17222200 Free article. Clinical Trial.
690 results